China
Africa
Explore chapters and articles related to this topic
Plant-Based Adjunct Therapy for Tuberculosis
Published in Namrita Lall, Medicinal Plants for Cosmetics, Health and Diseases, 2022
Lydia Gibango, Anna-Mari Reid, Jonathan L. Seaman, Namrita Lall
South African medicinal plants such as Pelargonium sidoides DC. and Pelargonium reniforme Curtis are traditionally used as infusions made from their tuberous, woody roots. Pelargonium sidoides DC. has a long history of use for medicinal purposes and for tuberculosis in particular. In 1897, an Englishman named Charles Henry Stevens who was suffering from tuberculosis was advised by his doctor to go to South Africa to cure the disease. In what is known as Lesotho today, he met Kagaitse, a Zulu man who was an expert on medicinal plants, and was given a boiled root preparation of the plant. After three months of treatment, Stevens was cured of tuberculosis (Bladt and Wagner, 2007). This plant, native to South Africa, was then taken to England by Stevens where today, the extract of the plant is sold all over Europe. In South Africa, it has long been used by the Zulu people to treat diarrhea, dysentery and gonorrhea (Drewes, 2012).
Respiratory tract infections
Published in Gina Johnson, Ian Hill-Smith, Chirag Bakhai, The Minor Illness Manual, 2018
Gina Johnson, Ian Hill-Smith, Chirag Bakhai
Pelargonium extract (Kaloba) has been shown in two trials (Timmer et al., 2013) to reduce sputum production in acute bronchitis and there is some evidence to support using andrographis paniculata and ivy/primrose/thyme herbal medicines (Wagner et al., 2015) but they may be difficult to obtain. The interactions of herbal medicines are not well understood, so they are best avoided if other regular medicines (particularly warfarin) are taken
Intellectual Property Rights and Traditional Medical Knowledge in Africa
Published in Charles Wambebe, African Indigenous Medical Knowledge and Human Health, 2018
Returning to the Pelargonium case, views are divided on how important traditional knowledge really is to the pharmaceutical industry and to drug discovery. For some, traditional knowledge subsidizes the pharmaceutical industry. For others, it has no relevance for present and future drug discovery, and cases such as Pelargonium are not that common and their significance is overstated. Dutfield asserts that the truth lies somewhere in between—while there is enough evidence to demonstrate that loss of traditional knowledge means cutting off access to a potentially huge and priceless stock of substances that scientists are unlikely to find on their own, one should not overestimate the value of traditional knowledge (Dutfield, 2011:237–243). As Dutfield points out, “the debate on the role of traditional knowledge in drug discovery and the extent to which this is exploitative is one characterized more by heat than light” (Dutfield, 2011:243).
GC-MS Profiling and Antineoplastic Activity of Pelargonium Inquinans Ait Leaves on Acute Leukaemia Cell Lines U937 and Jurkat
Published in Nutrition and Cancer, 2022
Ogochukwu Izuegbuna, Gloria A. Otunola, Graeme Bradley
One of these plants is Pelargonium inquinans, an aromatic plant and a member of the Geraniaceae family. Plants in this family are used by various traditional healers including the Xhosa, Sotho and Zulus for the management of various ailments. Their essential oils are also used in perfumery and aromatherapy5. The Pelargonium species are known to be abundant in polyphenols, coumarins, monoterpenes and sesquiterpenes which contribute to their anti-inflammatory activities6. Pelargonium inquinans is a woody shrub with velvety and glandular branches. It is indigenous to South Africa and found especially in the Eastern Cape up to southern Kwazulu- Natal. The local people use the stems and leaves to treat headaches and flu (SANBI). The plant’s crude extracts have been shown to have strong antioxidant activity7. The essential oils of Pelargonium inquinans have also been reported to demonstrate good nematocidal properties8. Not much has been reported about Pelargonium inquinans in the literature.
HL301 versus Umckamin in the treatment of acute bronchitis: a phase III, randomized, controlled, double-blind, multicenter study
Published in Current Medical Research and Opinion, 2020
Won-Young Kim, Myung Jae Park, Chin Kook Rhee, Sang Yeub Lee, Do Jin Kim, Dong Gyu Kim, Chang-Min Choi, Deog Kyeom Kim, Yee Hyung Kim, Ho Joo Yoon, Jae Yeol Kim
Pelargonium sidoides is a perennial plant found in different locations in South Africa. Traditionally, the plant material was used for treating common cold and cough. Its aqueous-ethanolic root extract, Umckamin is approved for the treatment of acute bronchitis and is widely used for treating acute and chronic respiratory tract infections14,15. It has many pharmacologic effects, especially antibacterial, as well as antiviral and immunomodulatory activities16,17. Although doubt exists, P sidoides was effective in alleviating symptoms of acute rhinosinusitis and the common cold in adults. Given that it is one of the rare herb extracts with effects that have been proven by multiple, well-designed, randomized, controlled trials, it was selected as an active comparator of HL301. We did not include a placebo arm in the present study because HL301 was proved to be more effective in the symptomatic treatment of acute bronchitis than placebo in the previous two studies7,8.
Effects of Pelargonium sidoides extract on chemokine levels in nasal secretions of patients with non-purulent acute rhinosinusitis
Published in Journal of Drug Assessment, 2020
Aleksandar Perić, Sandra Vezmar Kovačević, Aleksandra Barać, Dejan Gaćeša, Aneta V. Perić, Danilo Vojvodić
In our study, the patients reported no adverse effects. However, previous studies reported allergic reactions, hemorrhage and liver toxicity following therapy with extract of Pelargonium sidoides21,22. Therefore, a theoretical risk of interactions between active substances of this herbal medicine and anticoagulants such (e.g. warfarin), and antiplatelet drugs (e.g. aspirin) was notified. There are also cautions against use of the tested substance during pregnancy and lactation and in patients with serious liver diseases21,22. Regarding the duration of EPs 7630 administration in patients with common cold, previous studies showed that both pediatric and adult patients should receive treatment for a maximum of 7–10 days5,22,23. Due to the presence of more intensive and refractory symptoms in patients with APRS and the possibility of the presence of side effects of Pelargonium sidoides, we decided to administrate this herbal drug for 10 days.